サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747658

第3世代シーケンスの世界市場

Third Generation Sequencing

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
第3世代シーケンスの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

第3世代シーケンスの世界市場は2030年までに25億米ドルに達する

2024年に7億8,580万米ドルと推定される第3世代シーケンスの世界市場は、2024年から2030年にかけてCAGR 21.2％で成長し、2030年には25億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである第3世代シーケンス製品は、CAGR 22.8％を記録し、分析期間終了時には18億米ドルに達すると予測されます。第3世代シーケンスサービス分野の成長率は、分析期間のCAGRで17.4％と推定されます。

米国市場は推定2億660万米ドル、中国はCAGR20.0％で成長予測

米国の第3世代シーケンス市場は、2024年に2億660万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億8,020万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.6%と18.1%と予測されています。欧州では、ドイツがCAGR約14.4%で成長すると予測されています。

世界の「第3世代シーケンス」市場- 主要動向と促進要因のまとめ

ゲノムプレシジョン時代における第3世代シーケンスの特徴とは？

第3世代シーケンス（TGS）技術は、増幅を必要としないロングリード1分子シーケンスを提供することで、ゲノム解析の展望を再定義しました。以前のシーケンス技術からのこの進化は、生物学的研究、臨床診断、農業、進化科学に重大な影響を及ぼしています。Pacific BiosciencesのSMRTやOxford NanoporeのMinIONのようなTGSプラットフォームは、短いリードとエラーを起こしやすい増幅プロセスに大きく依存する第2世代の手法とは異なり、反復配列、構造変異、エピジェネティック修飾を含む複雑なゲノム領域にわたって、より高い忠実度で超ロングリードを提供します。これらの能力は、特に植物ゲノム、希少疾患遺伝学、がんの不均一性など、これまで困難であった領域において、完全なゲノムをde novoでアセンブルするために不可欠です。研究者はまた、TGSをトランスクリプトミクスに応用し、全長mRNAシーケンシングを行うことで、代替スプライシングやアイソフォーム発現の正確な検出を可能にしています。さらに、TGSはリアルタイムシーケンスを提供し、感染症発生時や病原体監視およびバイオセキュリティへの応用に不可欠な迅速なターンアラウンドタイムを可能にします。シーケンシング中にRNAを直接読み取り、メチル化パターンを検出する能力により、TGSは基礎研究と臨床の両方において革新的な技術として位置づけられています。

リアルタイムでポータブルなシーケンシングはゲノム診断の未来か？

可搬性とリアルタイム解析はTGSプラットフォームの特徴であり、臨床と現場の両方の環境で比類のない柔軟性を提供します。Oxford Nanopore MinIONのようなデバイスは、ポケットに入るほどコンパクトでありながら、遠隔地の村、戦場、宇宙ステーションなど、現場で複雑なゲノムシーケンスを実行できるほど強力です。これは公衆衛生、疫学、個別化医療にとって非常に大きな意味を持ちます。臨床診断では、リアルタイムシークエンシングにより、敗血症管理、院内感染、がんプロファイリングにおいて極めて重要な病原体の迅速な同定が可能になります。COVID-19パンデミックの際、TGSプラットフォームはリアルタイムのウイルスゲノム追跡のために世界的に展開され、変異のモニタリングと公衆衛生対応の指針としてその価値を示しました。法医学においては、TGSはDNAプロファイリングに新たな次元の精度と包括性を提供しています。ポータブル・プラットフォームはまた、農業科学者が現場で植物や動物のゲノムをモニターすることを可能にし、リアルタイムの育種決定、病気の検出、生物工学に役立っています。この機動性とリアルタイムのデータ出力が組み合わさることで、集中型研究所の必要性が大幅に減少し、資源が限られた環境でも高度なシーケンスが利用できるようになり、分散型、迅速、かつデータ豊富な診断への扉が開かれます。

第3世代シーケンスの採用を促進する技術的進歩とは？

TGSの進歩は、分子生物学、バイオインフォマティクス、装置工学における改良の収束によって推進されています。主な発展には、スループットの向上、エラー率の低減、ベースコールアルゴリズムの強化などがあり、これによりTGSプラットフォームは、ロングリードの利点を維持しながら、第二世代の精度に匹敵することができるようになりました。新しい酵素ケミストリー、ポアデザイン、シグナル処理法の導入により、リードの長さとスピードが向上し、同時に塩基あたりのコストが低下しました。バイオインフォマティクスツールも進歩し、TGSによって生成される膨大で複雑なデータセットを扱うためのスケーラブルなソリューションが提供され、クラウドベースのプラットフォームによってリアルタイムのゲノムデータ解析と共有が容易になりました。マルチプレキシング機能が拡大し、研究者は精度を損なうことなく複数のサンプルを同時にシーケンスできるようになりました。さらに、サンプル調製と自動化における技術革新は、作業時間とコンタミネーションのリスクを低減しています。いくつかのTGSツールのオープン・プラットフォームの性質は、広範な学術的・産業的協力を促し、特定のアプリケーションのための発見とカスタマイズを加速しています。このような技術的な勢いは、TGSを単に旧来の手法に取って代わるものとしてではなく、科学分野のスペクトル全体にわたって、最先端研究と商業的ブレークスルーを可能にする万能なものとして位置づけています。

第3世代シーケンス市場の成長は、いくつかの要因によって牽引されています。

第3世代シーケンス市場の急拡大は、技術、アプリケーション、行動力学の組み合わせによって促進されています。ヘルスケア分野では、精密診断と個別化治療計画に対する需要の高まりにより、複雑な構造変異、希少変異、エピジェネティックマーカーを検出できるシーケンスツールが必要とされています。腫瘍学では、リアルタイムかつ包括的なシーケンシングにより、個別化がん治療へのシフトが加速しています。感染症サーベイランスでは、TGSは病原体のほぼ瞬時のゲノム解析を可能にします。このニーズは、新興の抗生物質耐性株の増加により特に緊急性を増しています。農業分野では、食糧安全保障と遺伝子最適化作物の推進が、植物や動物のゲノム解析におけるTGSの導入に拍車をかけています。さらに、消費者直接遺伝子検査の人気が高まっていることから、より深い洞察を提供する包括的なシーケンス技術への関心が高まっています。高分解能、高スループットのゲノム科学への幅広い移行を反映し、学術機関やバイオテクノロジー新興企業は、研究インフラにTGSプラットフォームを組み込む傾向を強めています。また、ポータブルデバイスを活用したシーケンシングの非中央集権化は、ユーザーの行動を変革し、ポイントオブケア診断やデータアクセスの民主化を促しています。このような技術主導型およびエンドユーザー固有の力学が、市場の力強い成長軌道を後押ししています。

セグメント

コンポーネント（製品、サービス）、テクノロジー（1分子リアルタイムシーケンシング、ナノポアシーケンシング、合成ロングリードシーケンシング）、アプリケーション（ゲノムシーケンシング、エピジェネティクス、トランスクリプトミクス、メタゲノミクス、その他のアプリケーション）、エンドユーザー（バイオ製薬企業、病院・クリニック、契約研究機関、その他のエンドユーザー）

調査対象企業の例（注目の34社）

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN N.V.
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35878

Global Third Generation Sequencing Market to Reach US$2.5 Billion by 2030

The global market for Third Generation Sequencing estimated at US$785.8 Million in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 21.2% over the analysis period 2024-2030. Third Generation Sequencing Products, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Services segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$206.6 Million While China is Forecast to Grow at 20.0% CAGR

The Third Generation Sequencing market in the U.S. is estimated at US$206.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.2 Million by the year 2030 trailing a CAGR of 20.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.6% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global "Third Generation Sequencing" Market - Key Trends & Drivers Summarized

What Sets Third Generation Sequencing Apart in the Era of Genomic Precision?

Third Generation Sequencing (TGS) technologies have redefined the landscape of genomic analysis by offering long-read, single-molecule sequencing without the need for amplification. This evolution from earlier sequencing technologies has profound implications for biological research, clinical diagnostics, agriculture, and evolutionary science. Unlike second-generation methods, which rely heavily on short reads and error-prone amplification processes, TGS platforms such as Pacific Biosciences’ SMRT and Oxford Nanopore’s MinION deliver ultra-long reads with higher fidelity across complex genomic regions, including repetitive sequences, structural variants, and epigenetic modifications. These capabilities are critical for assembling complete genomes de novo, especially in previously intractable areas like plant genomes, rare disease genetics, and cancer heterogeneity. Researchers are also applying TGS to transcriptomics for full-length mRNA sequencing, allowing for accurate detection of alternative splicing and isoform expression. Additionally, TGS offers real-time sequencing, enabling rapid turnaround times critical during infectious disease outbreaks and for applications in pathogen surveillance and biosecurity. The ability to directly read RNA and detect methylation patterns during sequencing positions TGS as a transformative technology in both foundational research and clinical practice.

Is Real-Time and Portable Sequencing the Future of Genomic Diagnostics?

Portability and real-time analysis are hallmarks of TGS platforms, offering unmatched flexibility in both clinical and field environments. Devices like the Oxford Nanopore MinION are compact enough to fit in a pocket yet powerful enough to perform complex genomic sequencing on-site-be it a remote village, a battlefield, or a space station. This has enormous implications for public health, epidemiology, and personalized medicine. In clinical diagnostics, real-time sequencing enables faster pathogen identification, crucial in sepsis management, hospital-acquired infections, and cancer profiling. During the COVID-19 pandemic, TGS platforms were deployed globally for real-time viral genome tracking, showcasing their value in monitoring mutations and guiding public health responses. In forensic science, TGS offers new dimensions of accuracy and comprehensiveness for DNA profiling. Portable platforms are also enabling agricultural scientists to monitor plant and animal genomes in the field, aiding in real-time breeding decisions, disease detection, and bioengineering. This mobility-combined with real-time data output-greatly reduces the need for centralized laboratories, making advanced sequencing accessible even in resource-limited settings and opening the door to decentralized, rapid, and data-rich diagnostics.

What Are the Technological Advancements Driving Adoption of Third Generation Sequencing?

The progress in TGS is driven by a convergence of improvements in molecular biology, bioinformatics, and instrument engineering. Key developments include increased throughput, reduced error rates, and enhanced basecalling algorithms that now allow TGS platforms to rival second-generation accuracy while preserving the advantages of long reads. The introduction of new enzyme chemistries, pore designs, and signal processing methods has improved read lengths and speed, while simultaneously lowering costs per base. Bioinformatics tools have also advanced, offering scalable solutions to handle the vast and complex datasets generated by TGS, with cloud-based platforms facilitating real-time genomic data analysis and sharing. Multiplexing capabilities are expanding, allowing researchers to sequence multiple samples concurrently without compromising accuracy. Additionally, innovations in sample preparation and automation are reducing hands-on time and contamination risks. The open-platform nature of some TGS tools has encouraged broad academic and industrial collaboration, accelerating discovery and customization for specific applications. This technological momentum is positioning TGS not just as a replacement for older methods, but as a versatile enabler of cutting-edge research and commercial breakthroughs across a spectrum of scientific disciplines.

The Growth in the Third Generation Sequencing Market Is Driven by Several Factors…

The rapid expansion of the third generation sequencing market is being fueled by a combination of technological, application-specific, and behavioral dynamics. In the healthcare sector, the increasing demand for precision diagnostics and personalized treatment plans is necessitating sequencing tools capable of detecting complex structural variations, rare mutations, and epigenetic markers-capabilities where TGS outperforms conventional methods. In oncology, real-time and comprehensive sequencing is accelerating the shift toward individualized cancer therapies. In infectious disease surveillance, TGS enables near-instantaneous genomic analysis of pathogens, a need that has become especially urgent with the rise of emerging and antibiotic-resistant strains. In agriculture, the push for food security and genetically optimized crops is spurring adoption of TGS in plant and animal genomics. Furthermore, the growing popularity of direct-to-consumer genetic testing is driving interest in more comprehensive sequencing technologies that offer deeper insights. Academic institutions and biotech startups are increasingly incorporating TGS platforms into their research infrastructures, reflecting a broader transition to high-resolution, high-throughput genomic science. The decentralization of sequencing-empowered by portable devices-is also transforming user behavior, encouraging point-of-care diagnostics and democratized data access. These technology-driven and end-use-specific dynamics are collectively propelling the market’s robust growth trajectory.

SCOPE OF STUDY:

The report analyzes the Third Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Products, Services); Technology (Single-molecule Real-time Sequencing, Nanopore Sequencing, Synthetic Long-read Sequencing); Application (Genome Sequencing, Epigenetics, Transcriptomics, Metagenomics, Other Applications); End-User (Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN N.V.
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Third Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Real-Time, Long-Read Sequencing Propels Market Growth
    • Accelerated Adoption in Clinical Diagnostics Expands Addressable Market
    • Rising Incidence of Genetic Disorders and Cancer Drives Sequencing Uptake
    • Demand for Deeper Genome Insights Strengthens Business Case for Third Gen Platforms
    • Government Genomic Initiatives and Grants Spur R&D and Market Entry
    • Advances in Bioinformatics Tools Enhance Accuracy and Usability of Sequencing Data
    • Growing Use in Agriculture and Animal Genomics Broadens Market Scope
    • Declining Cost per Genome Sequenced Drives Mass Adoption
    • Personalized Medicine Boom Throws Spotlight on Rapid Sequencing Technologies
    • Emerging Use Cases in Pathogen Surveillance Sustain Market Momentum
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Third Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Metagenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Single-molecule Real-time Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Synthetic Long-read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • JAPAN
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CHINA
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • EUROPE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • FRANCE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • GERMANY
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION